MMP12 Diagnostics and Inhibition for Immune-Mediated Inflammatory Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and treating immune-mediated inflammatory diseases, such as Takayasu arteritis and giant cell arteritis, rely on IL-6 inhibitors, which can lead to long-term complications like large blood vessel stenosis and dilation, and there is a need for alternative biomarkers and treatments.
Innovation Solution
The use of MMP12 as a biomarker for diagnosing immune-mediated inflammatory diseases, through measuring MMP12 protein levels in biological samples, and developing diagnostic drugs and therapeutic agents that interact specifically with MMP12 to detect, predict, and treat these diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If IL-6 inhibitors are used for treating immune-mediated inflammatory diseases, then treatment effectiveness is improved, but long-term complications such as large blood vessel stenosis and dilation progress
Solution Approach 1:
The patent changes the therapeutic target from IL-6 to MMP12, representing a fundamental parameter change in the treatment approach. By targeting MMP12 instead of IL-6, the invention maintains treatment effectiveness while avoiding the harmful vascular complications associated with IL-6 inhibition
Solution Approach 2:
The patent extracts MMP12 as a specific therapeutic target from the broader inflammatory pathway. By identifying and targeting MMP12 specifically, the invention isolates a more precise therapeutic intervention point that avoids the off-target effects of IL-6 inhibition
2Measurement precision
If MMP12 is used as a biomarker for diagnosing immune-mediated inflammatory diseases, then diagnostic accuracy is improved, but reliance on IL-6 as an indicator is reduced
Solution Approach 1:
The patent replaces the established but problematic IL-6 indicator with MMP12 as a new diagnostic biomarker. This substitution provides a fresh measurement approach that maintains diagnostic capability while eliminating dependency on the flawed IL-6 pathway
Solution Approach 2:
The patent changes the diagnostic parameter from IL-6 levels to MMP12 levels. This parameter change enables accurate disease detection and monitoring while providing information independent of the IL-6 pathway, thereby reducing diagnostic dependency on that pathway
Data Source
Figure 1(A)~1(B)
Figure 2
Figure 3A~5D
AI summary
Provided are a method for detecting an immune-mediated inflammatory disease characterized by an increase in expression of MMP12, in a subject, a diagnostic drug containing a substance that specifically interacts with MMP12, and a therapeutic agent containing an MMP12 inhibitory substance.